Delivery Order HHSO100201400003I-HHSO10033002T

Award Date 8/20/15
Potential Completion Date 8/31/20
Potential Value $6.2M
Ultimate Awardee
PPD Development LP
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Cape Fear, NC 28401, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $16,382,387.80 cost-plus-fixed-fee delivery order awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to PPD Development, LP. The contract is for clinical services described in Tasks 1 through 15 under the ASPR-16-05933 requirement, which is part of the Medical Countermeasures Clinical Studies Network IDIQ contract vehicle. The contract is for a Heterologous Prime Boost Influenza Vaccine Trial and does not have a set-aside...
This is a $1,859,402 task order award under the National Institute of Allergy and Infectious Diseases' (NIAID) Early Phase Clinical Trial Units (EPCTU) indefinite delivery vehicle (IDV) contract. The prime contractor, PPD Development LP, is a global contract research organization that provides comprehensive clinical trial and research support services to federal agencies. This cost-plus-fixed-fee delivery order does not have a set-aside designation. PPD will perform the work in Cape Fear,...
This is a $5,758,524.34 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to PPD Development LP, a global contract research organization (CRO). The contract is to provide monitoring services for a Phase III clinical trial, specifically trial A5300B/PHOENIX. It is a cost-plus-fixed-fee contract with an ultimate completion date of December 14, 2025. The contract was awarded on April 15, 2019 and is not...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to PPD Development LP, a global contract research organization (CRO). The contract, valued at $64,031,927.00, is for completing the ACTIV 2 study to support COVID-19 research. The contract is a cost-plus-fixed-fee type and does not have a set-aside designation. PPD Development LP is a subsidiary of Thermo Fisher...
This is a firm-fixed price delivery order awarded by the Department of the Army Medical Command to PPD Development LP, a global contract research organization (CRO), in the amount of $198,044.52. The order is for labor analysis of alternatives for extremity repair in regards to vascular grafting services during the base period. This delivery order is under the Medical Product Research and Development contract vehicle. The contract has no set-aside designation. As a prime contractor, PPD has...
This is a $126,485,055.00 definitive time and materials contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The contract is for advanced research and development activities to support BARDA's continuing efforts on COVID-19 vaccine development, assessing the impact of variants on vaccine immunogenicity, and analyzing novel immunogenicity...
This is a federal contract award to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The $151,299.72 firm fixed-price delivery order was issued under the Medical Product Research and Development Indefinite Delivery Vehicle (IDV) with the U.S. Army Medical Command (MEDCOM). The contract does not have a set-aside designation. PPD Development LP provides comprehensive clinical trial and research support services to various federal...
This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to PPD Development LP, a global contract research organization (CRO). The contract, valued at $66,339,562.95, is for the TAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER and has a performance period ending on February 23, 2023. PPD Development LP, a subsidiary of Thermo Fisher...
This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to PPD Development LP for NIAID Clinical Site Monitoring services. The contract has a ceiling value of $140,719,763.00 and a period of performance ending on January 31, 2024. PPD Development LP is a global contract research organization (CRO) that provides clinical trial and research support services to federal...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $500,263.64 Delivery Order contract to PPD Development LP, a global contract research organization (CRO), for clinical site and study monitoring services in support of research partnerships for global mental health. The contract has a period of performance from September 28, 2018 to September 27, 2023 and is a labor hours type contract. PPD Development LP has provided over $500...

This is a delivery order under the Medical Countermeasures Clinical Studies Network contract vehicle, awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to PPD Development, LP, a global contract research organization (CRO). The $6,186,155.39 delivery order is for a H5N1 clinical study, under a cost-plus-fixed-fee contract type. PPD Development, LP has been awarded over $500 million in prime federal contracts and participated as a subcontractor on grants and contracts worth over $100 million, supporting a wide range of services for clinical trials and research studies related to vaccines, therapeutics, diagnostics, and medical countermeasures development. This delivery order does not utilize any set-aside designations.

Generated 7/4/24, 10:04 AM